Breast Cancer

This study aims to understand the degree of influence of the severity of lymphedema on quality of life in patients with breast cancer–related lymphedema during the maintenance phase.

In the non-HLA-A*02 arm of the FLAMINGO-1 trial, breast recurrence rates were less than 1% following treatment with GLSI-100.

The primary end point of PFS was met in the phase 3 FOURLIGHT-1 trial assessing atirmociclib plus fulvestrant in patients with HR+/HER2– breast cancer.

Julia E. McGuiness, MD, discussed the timeline for mammographic density changes following significant weight loss.

Key takeaways from the 43rd Miami Breast Cancer Conference focused on managing oligometastatic and oligoprogressive breast cancer with metastasis-directed therapy.

Tousimis explored the feasibility, complications, and surgical strategies for nipple-sparing mastectomy in patients with a history of radiation therapy.

The VIKTORIA-1 trial findings showed that gedatolisib plus fulvestrant with or without palbociclib significantly improved PFS in PIK3CA wild-type advanced breast cancer.

The FDA granted priority review to T-DXd for patients with HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.

Explore 5 essential takeaways for oncology clinicians regarding the use of GLP-1 receptor agonists in breast cancer management.

Arms 7 and 8 of the BEGONIA trial showed comparable outcomes for patients with different PD-L1 expression when receiving dato-DXd/durvalumab for TNBC.

A total of 46.6% of patients showed a favorable response to ultrahypofractionation radiotherapy for locally advanced breast cancer.

Sarah Poland, MD, discussed the landscape of immunotherapy in breast cancer, including clinical trial data, the rise of ADCs, and strategies for managing AEs.

A predetermined change control plan was authorized as part of the premarket approval, allowing for AI enhancements without the need for FDA oversight.

In the phase 3 neoCARHP trial, THP showed noninferior pathologic complete response rates compared with TCbHP in patients with HER2-positive breast cancer.

Patrick Borgen, MD, discussed using ctDNA for “molecular interception” to de-escalate surgery and minimize AEs in biology-driven breast cancer care.

Sarah Poland, MD, discussed the divergence between the IMpassion130 and IMpassion131 trials and the critical role of confirmatory trials in oncology.

Development of the oral DHX9 inhibitor, ATX-559, has been halted following adverse events in a phase 1/2 trial of patients with metastatic solid tumors.

The EGFR/HER3 bispecific ADC met the primary end points of PFS and OS in patients with advanced triple-negative breast cancer.

Sarah Poland, MD, discussed the transition of breast cancer from an "immunologically cold" tumor to a target for checkpoint inhibitors, highlighting the pivotal role of the KEYNOTE-012 trial.

A novel agent in combination with olaparib has been granted fast track designation by the FDA for germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.

Learn how ctDNA monitoring predicts breast cancer recurrence and detects ESR1/PIK3CA resistance, enabling earlier, personalized therapy switches.

Sarah Poland, MD, explored the evolution of immunotherapy in breast cancer, including in triple-negative disease and HR+ and HER2+ subtypes.

J. Isabelle Choi, MD, shared her specific fractionation preferences and prophylactic strategies to combat adverse effects associated with radiation.

A Prescription Drug User Fee Act date of December 18, 2026, has been set for giredestrant plus everolimus in ER+, HER2–, ESR1-mutated breast cancer.

Sunil W. Dutta, MD, discussed why clinical follow-up remains an essential soft skill for radiation oncologists in an increasingly automated field.